Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia2000 · 54 citations
2. 2Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study2003 · 155 citations
3. 3ECDEU Assessment Manual1976 · 1,850 citations
4. 4The dopamine connection1990 · 49 citations
5. 5The Brief Psychiatric Rating Scale2010 · 122 citations